Patients with invasive lung adenocarcinoma, without metastasis, some do not need chemotherapy. Lung adenocarcinoma is one of the most common pathologic types of lung cancer today, most often originating in the peripheral terminal bronchioles, and is more common in female patients. Except for a few carcinomas in situ that may be completely resected by surgery and exempted from chemotherapy, invasive lung adenocarcinoma indicates a risk of metastasis. The need for chemotherapy can be evaluated by a physician based on the patient’s TNM stage. Commonly used chemotherapy drugs for patients with lung adenocarcinoma include paclitaxel, vincristine, pemetrexed, and gemcitabine. In addition to chemotherapy, surgery is one of the current treatment options for lung adenocarcinoma. There are also patients who can benefit from radiotherapy. Lung adenocarcinoma patients should be guided by their oncologists in their treatment regimen.